PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

NCT06612814 | Active Not Recruiting Phase 3

• 1 other identifier: SCHBCC-N080
• Study Type: interventional
• Target: 307
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a prospective, open-label, phase III clinical study for patients with HR+/HER2- advanced breast cancer.

Conditions

Breast Cancer Metastatic

Outcome Measures

Primary Outcomes (1)

• PFS

  time to progressive disease (according to RECIST1.1)

  Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 5 years)

Secondary Outcomes (3)

• ORR

  andomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 5 years)

• CBR

  Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 5 years)

• OS

  Randomization to death from any cause, through the end of study (approximately 5 years)

Study Arms (2)

Cohort 1

EXPERIMENTAL

In this cohort, a patient would receive Dalpiciclib(CDK4/6 inhibitor) combined with Fluzoparib(Parp inhibitor) and endocrine therapy.

Drug: Fluzoparib; Drug: Dalpiciclib; Drug: Fulvestrant/AI

Cohort 2

ACTIVE COMPARATOR

In this cohort, a patient would receive Dalpiciclib(CDK4/6 inhibitor) combined with endocrine therapy.

Drug: Dalpiciclib; Drug: Fulvestrant/AI

Interventions

Fluzoparib DRUG

Parp inhibitor

Cohort 1

Dalpiciclib DRUG

CDK4/6 inhibitor

Cohort 1; Cohort 2

Fulvestrant/AI DRUG

Endocrine therapy

Cohort 1; Cohort 2

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Females ≥18 years and ≤ 75 years old;
• Histologically confirmed HR + / HER2- invasive breast cancer (specific definition: immunohistochemical detection of ER \> 10% tumor cell positive is defined as ER positive, PR \> 10% tumor cell positive is defined as PR positive, ER and / or PR Positive is defined as HR positive; HER2 0-1 + or HER2 is ++ but negative followed by FISH detection, no amplification, defined as HER2 negative);
• Subtype of similarity network fusion-3 (SNF-3) confirmed by the Department of Pathology and Key Laboratory of Breast Cancer of Fudan University Affiliated Cancer Hospital • Locally advanced breast cancer (incapable of radical local treatment) or recurrent metastatic breast cancer;
• Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1); or unmeasurable lytic or mixed (osteolytic + osteoblastic) bone lesions in the absence of measurable lesions;
• Has adequate bone marrow function: absolute neutrophil count \> 1.5x10ˆ9 /L; platelet count \> 75x10ˆ9 /L, hemoglobin \> 9g/dL;
• Patients had received no previous chemotherapy or targeted therapy for metastatic disease
• Has adequate liver function and kidney function: serum creatinine
• ECOG score ≤ 2 and life expectancy ≥ 3 months;
• Participants voluntarily joined the study, has signed informed consent before any trial related activities are conducted, has good compliance and has agreed to follow-up.

You may not qualify if:

• Treatment with chemotherapy, radiotherapy, immunotherapy or surgery (outpatient clinic surgery excluded) for metastatic disease
• Symptomatic, untreated, or actively progressing CNS metastases(glucocorticoids or mannitol needed to control symptoms);
• Significant cardiovascular disease(including congestive heart failure, angina pectoris, myocardial infarction or ventricular arrhythmia in the last 6 months);
• is pregnant or breast feeding;
• Malignant tumors in the past five years (except cured skin basal cell carcinoma and cervical carcinoma in situ).

Sponsors & Collaborators

• Zhimin Shao: lead
• First Hospital of China Medical University: collaborator
• Sun Yat-sen University: collaborator
• Chongqing University Cancer Hospital: collaborator
• Fujian Medical University Union Hospital: collaborator
• Ningbo Medical Center Lihuili Hospital: collaborator
• Shanghai First Maternity and Infant Hospital: collaborator
• Affiliated Hospital of Nantong University: collaborator
• Peking University Cancer Hospital & Institute: collaborator
• First Affiliated Hospital Xi'an Jiaotong University: collaborator
• Liaoning Cancer Hospital & Institute: collaborator
• Northern Jiangsu People's Hospital: collaborator
• Shanghai 6th People's Hospital: collaborator

Study Sites (1)

breast cancer institute of Fudan University Cancer Hospital

Shanghai, Shanghai Municipality, China

Location

MeSH Terms

Interventions

fluzoparib; dalpiciclib

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: director

Study Record Dates

• First Submitted: September 21, 2024
• First Posted: September 25, 2024
• Study Start: September 1, 2024
• Primary Completion (Estimated): October 30, 2027
• Study Completion (Estimated): April 30, 2028
• Last Updated: September 25, 2024

Record last verified: 2024-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)